Beyond benzodiazepines: Alternative pharmacologic agents for the treatment of insomnia

Annals of Pharmacotherapy

Volumn 32, Issue 6, 1998, Pages 680-691

  Wagner, Judy ^a,b   Wagner, Mary L ^a,c   Hening, Wayne A ^d  

^a RUTGERS UNIVERSITY   (United States)

^b SAINT BARNABAS MEDICAL CENTER   (United States)

^c Rutgers University   (United States)

^d UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY   (United States)

Author keywords

Hypnotics; Insomnia

Indexed keywords

ALCOHOL; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; ANTIHISTAMINIC AGENT; BARBITURIC ACID DERIVATIVE; BENZODIAZEPINE; CHLORAL HYDRATE; ESTAZOLAM; ETHCHLORVYNOL; FLUNITRAZEPAM; FLURAZEPAM; GLUTETHIMIDE; IMIDAZOPYRIDINE DERIVATIVE; LOPRAZOLAM; LORMETAZEPAM; MELATONIN; NITRAZEPAM; PYRAZOLOPYRIMIDINE DERIVATIVE; QUAZEPAM; TEMAZEPAM; TRAZODONE; TRIAZOLAM; VALERIAN; ZALEPLON; ZOLPIDEM; ZOLPIDEM TARTRATE; ZOPICLONE;

ANTEROGRADE AMNESIA; COGNITIVE THERAPY; DISEASE CLASSIFICATION; DRUG CONTRAINDICATION; DRUG DEPENDENCE; DRUG TOLERANCE; GASTROINTESTINAL SYMPTOM; HUMAN; INSOMNIA; NEUROLOGIC DISEASE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RELAXATION TRAINING; RESPIRATION DEPRESSION; REVIEW; SLEEP PARAMETERS;

ACETAMIDES; BENZODIAZEPINES; CLINICAL PROTOCOLS; HUMANS; HYPNOTICS AND SEDATIVES; MELATONIN; PHYTOTHERAPY; PIPERAZINES; PLANTS, MEDICINAL; PYRIDINES; PYRIMIDINES; RECEPTORS, GABA-A; SLEEP; SLEEP INITIATION AND MAINTENANCE DISORDERS; VALERIAN;

EID: 0031777762     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.17111     Document Type: Review

References (118)

1. Byerley B, Gillin JC. Diagnosis and management of insomnia. Psychiatr Clin North Am 1984;7:773-89.
2. Stoller MK. Economic effects of insomnia. Clin Ther 1994;16:873-97.
3. Walsh JK, Engelhardt CL. Trends in the pharmacologic treatment of insomnia. J Clin Psychiatry 1992;53(suppl 12):S10-7.
4. The Gallup Organization. Sleep in America: a national survey of U.S. adults. Washington, DC: National Sleep Foundation, 1995.
5. National Institutes of Health Consensus Development Conference Statement: the treatment of sleep disorders of older people. Sleep 1991;14: 169-77.
6. Dement WC. The proper use of sleeping pills in the primary care setting. J Clin Psychiatry 1992;53(suppl 12):S50-6.
7. Kales A, Kales JD. The study and nature of sleep. In: Kales A, Kales JD, eds. Evaluation and treatment of insomnia. New York: Oxford University Press, 1984:3-35.
8. Carskadon MA, Dement WC. Normal human sleep: an overview. In: Kryger MG, Roth T, Dement WC, eds. Principles and practice of sleep medicine. Philadelphia: WB Saunders Co., 1994:16-25.
9. Karni A, Tanne D, Rubenstein BS, Askenasy JM, Sagi D. Dependence on REM sleep of overnight improvement of a perceptual skill. Science 1994;265:679-82.
10. Hartman E. Nightmares and other dreams. In: Kryger MG, Roth T, Dement WC, eds. Principles and practice of sleep medicine. Philadelphia: WB Saunders Co., 1994:407-10.
11. Mendelson WB. An introduction to sleep studies. In: Mendelson WB, ed. Human sleep: research and clinical care. New York: Plenum Publishing Corp., 1987:3-31.
12. American Sleep Disorders Association. Glossary of terms used in sleep disorders medicine. In: Chokroverty S, ed. Sleep disorders medicine: basic science, technical considerations and clinical aspects. Boston: Butterworth-Heinemann, 1994:473-81.
13. Ashton H. Guidelines for the rational use of benzodiazepines: when and what to use. Drugs 1994;48:25-40.
14. Diagnostic Classification Steering Committee of the American Sleep Disorders Association (Thorpy MJ, chair). International classification of sleep disorders - diagnostic and coding manual. Rochester, MN: American Sleep Disorders Association, 1990.
15. National Institutes of Health Consensus Development Conference. Drugs and insomnia: the use of medications to promote sleep. JAMA 1984;251:2410-4.
16. Maczaj M. Pharmacological treatment of insomnia. Drugs 1993;45:44-55.
17. Bootzin RR, Perils ML. Nonpharmacologic treatments of insomnia. J Clin Psychiatry 1992;53(suppl 6):S37-41.
18. Spielman AJ, Caruso LS, Glovinsky PB. A behavioral perspective on insomnia treatment. Psychiatr Clin North Am 1987;10:541-53.
19. Nino-Murcia G. Diagnosis and treatment of insomnia and risks associated with lack of treatment. J Clin Psychiatry 1992;53(suppl 12):S43-7.
20. Trenkwalder C, Walters AS, Hening WA. Periodic limb movements and restless legs syndrome. Neurol Clin 1996;14:629-50.
21. Mahowald MW, Schenck CH. REM-sleep behavior disorder. In: Thorpy MJ, ed. Handbook of sleep disorders. New York: Marcel Dekker, 1990: 567-93.
22. Wooten V. Sleep disorders in psychiatric illness. In: Chokroverty S, ed. Sleep disorders medicine: basic science, technical considerations and clinical aspects. Boston: Butterworth-Heinemann, 1994:337-47.
23. Ware JC. Tricyclic antidepressants in the treatment of insomnia. J Clin Psychiatry 1983;44(9 pt 2):25-8.
24. Nierenberg AA, Adler LA, Peselow E, Zomberg G, Rosenthal M. Trazodone for antidepressant-associated insomnia. Am J Psychiatry 1994; 151:1069-72.
25. Scharf MB, Sachais BA. Sleep laboratory evaluation of the effects and efficacy of trazodone in depressed insomniac patients. J Clin Psychiatry 1990;51(suppl 9):S13-7.
26. Walsh JK, Beer B, Erman M, Erwin CW, Fry J, Karacan I, et al. Treatment of primary insomnia comparing zaleplon, triazolam and placebo (abstract). Sleep Res 1995;24:363.
27. Roth T, Roehrs TA, Fortier J, Koshorek G, Fry J, Vogel G, et al. Dose response effects of a new hypnotic in insomniacs (abstract). Sleep Res 1995;24:53.
28. Dietrich B, Farr I. Zaleplon: dose - response evaluation in primary insomnia (abstract). Sleep Res 1995;24a:116.
29. Hoehns JD, Perry PJ. Zolpidem: a nonbenzodiazepine hypnotic for treatment of insomnia. Clin Pharm 1993;12:814-28.
30. Wadworth AN, McTavish D. Zopiclone: a review of its pharmacological properties and therapeutic efficacy as an hypnotic. Drugs Aging 1993;3: 441-59.
31. Goa KL, Heel RC. Zopiclone, a review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy as an hypnotic. Drugs 1986;32:48-65.
32. Gillin JC, Byerley WF. The diagnosis and management of insomnia. N Engl J Med 1990;322:239-48.
33. Vgontzas AN, Kales A, Bixler EO. Benzodiazepine side effects: role of pharmacokinetics and pharmacodynamics. Pharmacology 1995;51:205-23.
34. Roth T, Roehrs TA. Issues in the use of benzodiazepine therapy. J Clin Psychiatry 1992;53(suppl 6):S14-8.
35. Roth T, Roehrs TA. A review of the safety profiles of benzodiazepine hypnotics. J Clin Psychiatry 1991;52(suppl 9):S38-41.
36. Mendelson WB. Clinical distinctions between long-acting and short-acting benzodiazepines. J Clin Psychiatry 1992;53(suppl 12):S4-7.
37. Salvà P, Costa J. Clinical pharmacokinetics and pharmacodynamics of zolpidem: therapeutic implications. Clin Pharmacokinet 1995;29:142-53.
38. Mendelson WB, Jain B. An assessment of short-acting hypnotics. Drug Saf 1995;13:257-70.
39. Sanger DJ, Benavides J, Perrault G, Morel E, Cohen C, Joly D, et al. Recent developments in the behavioral pharmacology of benzodiazepine (ω) receptors: evidence for the functional significance of receptor subtypes. Neurosci Behav Rev 1994;18:355-72.
40. Wamsley JK, Hunt MA. Relative affinity of quazepam for type-1 benzodiazepine receptors in brain. J Clin Psychiatry 1991;52(suppl 9):S15-20.
41. A receptors. Neuropharmacology 1992;31:693-700.
42. Kales A. Quazepam: hypnotic efficacy and side effects. Pharmacotherapy 1990;10:1-12.
43. Palminteri R, Narbonne G. Safety profile of zolpidem. In: Sauvanet JP, Langer SZ, Morselli PL, eds. Imidazopyridines in sleep disorders: a novel experimental and therapeutic approach. New York: Raven Press, 1988:351-61.
44. Markowitz JS, Rames LJ, Reeves N, Thomas SG. Zolpidem and hallucinations (letter). Ann Emerg Med 1997;29:300-1.
45. Pies RW. Dose-related sensory distortions with zolpidem (letter). J Clin Psychiatry 1995;56:35-6.
46. Mendelson WB. Sleepwalking associated with zolpidem (letter). J Clin Psychopharmacol 1994;14:150.
47. Sicard BA, Trocherie S, Moreau J, Vieillefond H, Court LA. Evaluation of zolpidem on alertness and psychomotor abilities among aviation ground personnel and pilots. Aviat Space Environ Med 1993;64:371-5.
48. Fairweather DB, Kerr JS, Hindmarch I. The effects of acute and repeated doses of zolpidem on subjective sleep, psychomotor performance and cognitive function in elderly volunteers. Eur J Clin Pharmacol 1992;43: 597-601.
49. Berlin I, Warot D, Hergueta T, Molinier P, Bagot C, Puech AJ. Comparison of the effects of zolpidem and triazolam on memory functions, psychomotor performances, and postural sway in healthy subjects. J Clin Psychopharmacol 1993;13:100-6.
50. Wesensten NJ, Balkin TJ, Belenky GL. Effects of daytime administration of zolpidem versus triazolam on memory. Eur J Clin Pharmacol 1995;48:115-22.
51. Monti JM. Effect of zolpidem on sleep in insomniac patients. Eur J Clin Pharmacol 1989;36:461-6.
52. Shaw SH, Curson H, Coquelin JP. A double-blind, comparative study of zolpidem and placebo in the treatment of insomnia in elderly psychiatric in-patients. J Int Med Res 1992;20:150-61.
53. Kryger MH, Steljes D, Pouliot Z, Neufeld H, Odynski T. Subjective versus objective evaluation of hypnotic efficacy: experience with zolpidem. Sleep 1991;14:399-407.
54. Monti JM, Attali P, Monti D, Zipfel A, de la Giclais B, Morselli PL. Zolpidem and rebound insomnia - a double blind, controlled polysomnographic study in chronic insomniac patients. Pharmacopsychiatry 1994;27:166-75.
55. Jonas JM, Coleman BS, Sheriden AQ, Kalinske RW. Comparative clinical profiles of triazolam versus other shorter-acting hypnotics. J Clin Psychiatry 1992;53(suppl 12):S19-31.
56. Scharf MB, Roth T, Vogel GW, Walsh JK. A multicenter placebo-controlled study evaluating zolpidem in the treatment of chronic insomnia. J Clin Psychiatry 1994;55:192-9.
57. Schlich D, L'Heritier C, Coquelin JP, Attali P. Long-term treatment of insomnia with zolpidem: a multicentre general practitioner study of 107 patients. J Int Med Res 1991;19:271-9.
58. Kummer J, Guendel L, Linden J, Eich FX, Attali P, Coquelin JP, et al. Long-term polysomnographic study of the efficacy and safety of zolpidem in elderly psychiatric in-patients with insomnia. J Int Med Res 1993;21:171-84.
59. Cavallaro R, Regazetti MG, Covelli G, Smeraldi E. Tolerance and withdrawal with zolpidem (letter). Lancet 1993;342:374-5.
60. Gericke CA, Ludolph AC. Chronic abuse of zolpidem (letter). JAMA 1994;272:1721-2.
61. Steens RD, Pouliot Z, Millar TW, Kryger MH, George CP. Effects of zolpidem and triazolam on sleep and respiration in mild to moderate chronic obstructive pulmonary disease. Sleep 1993;16:318-26.
62. Murciano D, Armengaud MH, Cramer PH, Neveux E, L'Héritier C, Pariente R, et al. Acute effects of zolpidem, triazolam, and flunitrazepam on arterial blood gases and control of breathing in severe COPD. Eur Respir J 1993;6:625-9.
63. Girault C, Muir J, Mihaltan F, Borderies P, De La Giclais B, Verdure A, et al. Effects of repeated administration of zolpidem on sleep, diurnal and nocturnal respiratory function, vigilance, and physical performance in patients with COPD. Chest 1996;110:1203-11.
64. Cirignotta F, Mondini S, Zucconi M, Gerardi R, Farfoli A, Lugaresi E. Controlled polysomnographic study of the effects of benzodiazepines and non benzodiazepine hypnotics (zolpidem) in obstructive sleep apnea patients: preliminary results. In: Sauvanet JP, Langer SZ, Morselli PL, eds. Imidazopyridines in sleep disorders: a novel experimental and therapeutic approach. New York: Raven Press, 1988:297-304.
65. Product information. Ambien (zolpidem tartrate). Chicago: GD Searle & Co., 1996.
66. van der Kleijn E. Effects of zopiclone and temazepam on sleep, behaviour and mood during the day. Eur J Clin Pharmacol 1989;36:247-51.
67. Pull CB, Dreyfus JF, Brun JP. Comparison of nitrazepam and zopiclone in psychiatric patients. Pharmacology 1983;27(suppl 2):S205-9.
68. Warot D, Bensimon G, Danjou P, Puech AJ. Comparative effects of zopiclone, triazolam and placebo on memory and psychomotor performance in healthy volunteers. Fundam Clin Pharmacol 1987;1:145-52.
69. Lader M. Rebound insomnia and newer hypnotics. Psychopharmacology 1992;108:248-55.
70. Begg EJ, Robson R, Frampton CM, Campbell JE. A comparison of efficacy and tolerance of the short acting sedatives midazolam and zopiclone. N Z Med J 1992;105:428-9.
71. Dorian P, Sellers EM, Kaplan H, Hamilton C. Evaluation of zopiclone physical dependence liability in normal volunteers. Pharmacology 1983; 27(suppl 2):S228-34.
72. Thakore J, Dinan TG. Physical dependence following zopiclone usage: a case report. Hum Psychopharmacol Clin Exp 1992;7:143-5.
73. Aranko K, Henriksson M, Hublin C, Seppalainen AM. Misuse of zopiclone and convulsions during withdrawal. Pharmacopsychiatry 1991;24: 138-40.
74. Muir JF, DeFouilloy C, Broussier R. Comparative study of the effects of zopiclone and placebo on respiratory function in patients with chronic obstructive respiratory insufficiency, Int Clin Psychopharmacol 1990;5 (suppl 2):S85-94.
75. Allain H, Delahaye C, Le Coz F, Blin P, Decombe R, Martinet JP. Post-marketing surveillance of zopiclone in insomnia: analysis of 20,513 cases. Sleep 1991;14:408-13.
76. Vanover KE, Barren JE. Evaluation of the discriminative stimulus effects of the novel sedative-hypnotic CL 284,846. Psychopharmacology 1994;115:289-96.
77. Beer B, Ieni JR, Wu W, Clody D, Amorusi P, Rose J, et al. A placebo-controlled evaluation of single, escalating doses of CL 284,846, a non-benzodiazepine hypnotic. J Clin Pharmacol 1994;34:335-44.
78. Vanover KE, Mangano RM, Barrett JE. Cl 284,846, a novel sedative-hypnotic: evaluation of its metabolites for pharmacological activity in vitro and in vivo. Drug Dev Res 1994;33:39-45.
79. Allen D, Curran HV, Lader M. The effects of single doses of Cl 284,846, lorazepam, and placebo on psychomotor and memory function in normal male volunteers. Eur J Clin Pharmacol 1993;45:313-20.
80. Roth T, Roehrs T, Zorick F, Conway W. Pharmacological effects of sedative-hypnotics, narcotic analgesics, and alcohol during sleep. Med Clin North Am 1985;69:1281-9.
81. Wincor MZ, Cyr M. Sleep disorders. In: Herfindel ET, Gourley DR, eds. Textbook of therapeutics: drug and disease management. Baltimore: Williams & Wilkins, 1996:1133-52.
82. Lindahl O, Lindwall L. Double blind study of a valerian preparation. Pharmacol Biochem Behav 1989;32:1065-6.
83. Schulz H, Stolz C, Müller J. The effect of valerian extract on sleep polygraphy in poor sleepers: a pilot study. Pharmacopsychiatry 1994;27: 147-51.
84. Balderer G, Borbély AA. Effect of valerian on human sleep. Psychopharmacology 1985;87:406-9.
85. Leathwood PD, Chauffard F, Heck E, Munoz-Box R. Aqueous extract of valerian root (Valeriana officinalis L.) improves sleep quality in man. Pharmacol Biochem Behav 1982;17:65-71.
86. Leathwood PD, Chauffard F. Aqueous extract of valerian reduces latency to fall asleep in man. Planta Med 1985;51:144-8.
87. Dollins AB, Zhdanova IV, Wurtman RJ, Lynch HJ, Deng MH. Effect of inducing nocturnal serum melatonin concentrations in daytime on sleep, mood, body temperature, and performance. Proc Natl Acad Sci 1994;91:1824-8.
88. Zhdanova IV, Wurtman RJ, Lynch HJ, Ives JR, Dollins AB, Morabito C, et al. Sleep-inducing effects of low doses of melatonin ingested in the evening. Clin Pharmacol Ther 1995;57:552-8.
89. Zhdanova IV, Wurtman RJ, Morabito C, Piotrovska VR, Lynch HJ. Effects of low oral doses of melatonin given 2-4 hours before habitual bedtime, on sleep in normal young humans. Sleep 1996;19:423-31.
90. Arendt J, Borbely AA, Franey C, Wright J. The effects of chronic, small doses of melatonin given in the late afternoon on fatigue in man: a preliminary study. Neurosci Lett 1984;45:317-21.
91. Nave R, Peled R, Lavie P. Melatonin improves evening napping. Eur J Pharmacol 1995;275:213-6.
92. James SP, Mendelson WB, Sack DA, Rosenthal NE, Wehr TA. The effect of melatonin on normal sleep. Neuropsychopharmacology 1987;1: 41-4.
93. James SP, Sack DA, Rosenthal NE, Mendelson WB. Melatonin administration in insomnia. Neuropsychopharmacology 1990;3:19-23.
94. Haimov I, Lavie P, Laudon M, Herer P, Vigder C, Zisapel N. Melatonin replacement therapy of elderly insomniacs. Sleep 1995;18:598-603.
95. Garfinkel D, Laudon M, Nof D, Zisapel N. Improvement of sleep quality in elderly people by controlled release melatonin. Lancet 1995;346: 541-4.
96. Ellis CM, Lemmens G, Parkes JD. Melatonin and insomnia. J Sleep Res 1996;5:61-5.
97. Hobbs C. Valerian. HerbalGram 1989;21:19-34.
98. Houghton PJ. The biological activity of valerian and related plants. J Ethnopharmacol 1988;22:121-42.
99. Mennini T, Bernasconi P, Bombardelli E, Morazzoni P. In vitro study on the interaction of extracts and pure compounds from Valeriana officinalis roots with GABA, benzodiazepine and barbiturate receptors in rat brain. Fitoterapia 1993;64:291-300.
100. MacGregor FB, Abernathy VE, Dahabra S, Cobden I, Hayes PC. Hepatotoxicty of herbal remedies. Br Med J 1989;299:1156-7.
101. Tortarolo M, Braun R, Hübner GE, Maurer HR. In vitro effects of epoxide-bearing valepotriates on mouse early hematopoietic progenitor cells and human T-lymphocytes. Arch Toxicol 1982;51:37-42.
102. Williamson JS, Wyandt CM. Herbal therapies: the facts and the fiction. Drug Topics 1997:78-85.
103. Lewy AJ, Saeeduddin A, Latham Jackson JM, Sack RL. Melatonin shifts human circadian rhythms according to a phase-response curve. Chronobiol Int 1992;9:380-92.
104. Dahlitz M, Alvarez B, Vignau J, English J, Arendt J, Parkes JD. Delayed sleep phase syndrome response to melatonin. Lancet 1991;337: 1121-4.
105. Claustrat B, Brun J, David M, Sassolas G, Chazot G. Melatonin and jet lag: confirmatory result using a simplified protocol. Biol Psychiatry 1992;32:705-11.
106. Waldhauser F, Saletu B, Trinchard-Lugan I. Sleep laboratory investigations on hypnotic properties of melatonin. Psychopharmacology 1990; 100:222-6.
107. MacFarlane JG, Cleghorn JM, Brown GM, Streiner DL. The effects of exogenous melatonin on the total sleep time and daytime alertness of chronic insomniacs: a preliminary study. Biol Psychiatry 1991;30:371-6.
108. Tzischinsky O, Pal I, Epstein Y, Dagan Y, Lavie P. The importance of timing in melatonin administration in a blind man. J Pineal Res 1992; 12:105-11.
109. Jan JE, O'Donnell ME. Use of melatonin in the treatment of paediatric sleep disorders. J Pineal Res 1996;21:193-9.
110. Jan JE, Espezel H, Appleton RE. The treatment of sleep disorders with melatonin. Dev Med Child Neurol 1994;36:97-107.
111. Waldhauser F, Lynch HJ, Wurtman RJ. Melatonin in human body fluids: clinical significance. In: Reiter RJ, ed. The pineal gland. New York: Raven Press, 1984:345-69.
112. Waldhauser F, Waldhauser M, Lieberman HR, Deng M, Lynch HJ, Wurtman RJ. Bioavailability of oral melatonin in humans. Neuroendocrinology 1984;39:307-13.
113. Zhdanova IV, Lynch HJ, Wurtman RJ. Melatonin: a sleep-promoting hormone. Sleep 1997;20:899-907.
114. Chronic melatonin use "cannot be justified for any sleep disorder." F-D-C Rep 1996;34(4):13-4.
115. Maestroni G. The immunoneuroendocrine role of melatonin. J Pineal Res 1993;14:1-10.
116. Voordouw BC, Euser R, Verdonk RE, Alberda BT, De Jong FH, Drogendijk AC, et al. Melatonin and melatonin-progestin combinations alter pituitary-ovarian function in women and can inhibit ovulation. J Clin Endocrinol Metab 1992;74:108-17.
117. Weekly LB. Effects of melatonin on pulmonary and coronary vessels are exerted through perivascular nerves. Clin Auton Res 1993;3:45-7.
118. Carman JS, Post RM, Buswell R, Goodwin FK. Negative effects of melatonin on depression. Am J Psychiatry 1976;133:1181-6.